Anti Vegf Eylea 2mg denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti vegf eylea 2mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Eylea (aflibercept 2 mg) for Prior Authorization

A prior-authorization (PA) denial or "prior auth required" denial means the claim was submitted — or the drug was administered — without an approved prior authorization on file with UHC, or that an existing authorization has lapsed. For anti-VEGF agents including Eylea 2 mg, UHC routinely requires PA before each course of treatment and may require re-authorization on a set schedule. These denials are typically the most correctable of all denial types because the clinical information needed to obtain authorization already exists in the chart.

## Why This Denial Is Appealable

Even when a PA was not obtained prospectively, retroactive authorization is available in most plans when the treatment was medically necessary and the failure to obtain PA was due to an administrative error, an emergency, or a prescriber oversight rather than a deliberate circumvention. Plans are also required under ERISA and ACA rules to disclose the specific PA criteria and cannot deny solely because of a procedural failure if clinical necessity is otherwise established. If the PA was submitted and was denied — rather than simply not obtained — the denial is subject to the standard internal and external appeal process.

## Your Federal Appeal Rights

• Retroactive PA request: If treatment was already provided without PA, submit a retroactive authorization request first, accompanied by full clinical documentation. Many UHC commercial plans allow a retroactive window.
• Internal appeal (ERISA §503 / ACA): File within the deadline on your denial letter. The appeal must address both the procedural question (why PA was not obtained in advance) and the clinical question (why treatment was medically necessary).
• External review (ACA §2719): If the internal appeal is denied on clinical grounds, escalate to an IRO within approximately four months.
• Expedited appeal: If ongoing therapy is at risk and delay would harm your vision, request the 72-hour expedited track.

## Documentation to Gather

1. PA submission record — confirm with your prescriber's office whether a PA was submitted, when, and what response (if any) was received; obtain the submission reference number. 2. Diagnosis and imaging — current ophthalmology notes, OCT findings, and visual acuity data supporting medical necessity. 3. Treatment history — prior injection dates, responses, and any documentation showing continuity of care. 4. Prescriber letter — a signed medical-necessity letter addressed specifically to UHC's anti-VEGF PA criteria, explaining why Eylea 2 mg was required and why any procedural lapse should be excused. 5. UHC PA criteria — obtain UHC's published prior-authorization criteria for anti-VEGF agents so the prescriber's letter can address each criterion directly.

## Criteria-Mapping Structure

For PA-related appeals, your criteria map should have two sections. The first addresses any procedural deficiency (explain the circumstances of the missed PA). The second mirrors the clinical PA criteria from UHC's policy — each criterion in the left column, the supporting chart fact in the right. Reviewers and IROs are required to evaluate the clinical record on its merits even when a procedural argument is also present.